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Methods and Materials: This study is a historical cohort type of study and is con‐

multiforme (GBM) and giant cell glioblastoma (GCG) regarding mortality and progno‐
sis among adults and elderly patients in the U.S.
ducted on adults and elderly individuals with GBM or GCG from the years 1985–
2014 in the U.S. Data were collected from the Surveillance, Epidemiology, and End
Results Program (SEER) database. The study exposure was GBM or GCG and the
outcome was mortality. The potential confounders were age, sex, race, ethnicity, year
of diagnosis, primary site, brain overlap, and surgery. A chi‐square test was used for
categorical data. A univariate analysis was used for variables having a p‐value <.05.
Potential confounders were selected and evaluated using multivariate logistic regres‐
sion models to calculate the odds ratio with stepwise selection.
Results: The study sample was 25,117. The incidences of GBM and GCG were not
similar in relation to age group. Also, Spanish–Hispanic ethnicity was independently
protective of GBM and GCG as compared to Non‐Spanish–Hispanic ethnicity pa‐
tients with GBM have a higher mortality rate than do GCG patients. The mortality
rate was higher among patients diagnosed before 2010.
Conclusion: GCG was not statistically significant in association to reduced mortal‐
ity. Non‐Spanish–Hispanics with GBM or GCG had a higher mortality rate than did
Spanish–Hispanics. Factors such as being female, being age 59–65, and having a year
of diagnosis before 2010 were independently associated with increased mortality.
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1 | I NTRO D U C TI O N

elderly individuals (SEER Program). Giant cell glioblastoma (GCG) is
a rare neoplasm characterized by a predominance of bizarre multi‐

Brain cancer and other nervous system cancers are the tenth leading

nucleated giant cells with abundant eosinophilic cytoplasm. (Ohgaki,

cause of death in the U.S. Brain cancer is common among adults and

Peraud, Nakazato, Watanabe, & Deimling, 2000).

The work was conducted in Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA with cooperation with College of Medicine, Imam Mohammad Ibn
Saud Islamic University, Riyadh, Saudi Arabia.
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Significant efforts to characterize this unusual malignancy have

the past few years. Therefore, the current study aimed to find the

established a glial origin, and it is now considered a subtype of glio‐

differences between GBM and GCG regarding mortality and prog‐

blastoma multiforme (GBM; Akslen, Mork, Larsen, & Myrseth, 1988;

nosis among adults and elderly patients in the U.S.

Becker, Benyo, & Roessmann, 1967; Hadfield & Silverberg, 1972; Katoh
et al., 1995; Kawano et al., 1995; Margetts & Kalyan‐Raman, 1989).
GCG has been reported to represent between 2% and 5% of
GBM cases (Artico, Cervoni, Celli, Salvati, & Palma, 1993; Palma,
Celli, Maleci, Di Lorenzo, & Cantore, 1989; Shinojima et al., 2004).

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Study strategy and data source

Importantly, several small series and case reports have sug‐

A historical cohort was assembled using data from the Surveillance,

gested that the prognosis of GCG is significantly better than that

Epidemiology, and End Results (SEER) database in July 2017 (http://

observed for GBM (Akslen et al., 1988; Becker et al., 1967; Burger

www.seer.cancer.gov/). The data were collected via SEER*Stat soft‐

& Vollmer, 1980; Chang, Kuwana, Ito, Koike, & Kitamura, 2001; Deb,

ware from 1985 to 2014. The SEER program was established in 1973

Sharma, Chander, Mahapatra, & Sarkar, 2006; Gullotta, Casentini, &

by the U.S. NCI and collects incidences and survival records of pa‐

Neumann, 1980; Klein, Molenkamp, Sorensen, & Roggendorf, 1998;

tients with malignant tumors from 18 population‐based cancer reg‐

Kroh, Matyja, Marchel, & Bojarski, 2004; Margetts & Kalyan‐Raman,

istries in the U.S. (SEER). The registries represent approximately 28%

1989; Sabel, Reifenberger, Weber, Reifenberger, & Schmitt, 2001;

of the population of the U.S.; registries were selected, in part, for

Shinojima et al., 2004). The development of GBG is highly related to

their diverse population subgroups. These surveys have multistage

mutations of the TP53 gene (Kleihues & Glioblastoma,)

sampling and are considered to be complex, overestimated, and not

MGMT promoter methylation, mutations in the IDH1/2 genes,
or BRAF mutations, which are actually used as diagnostic, prog‐

representative of the entire U.S. population. However, SEER does its
own modeling through extrapolation.

nostic, and predictive molecular markers in anaplastic glial tumors
(Lohkamp et al., 2016).
Glioblastoma multiforme is a common malignant tumor that orig‐

2.2 | Study population

inates from astrocytes. It is a rapid‐growing tumor that affects the

Patients aged younger than 20 years have a lower incidence rate;

nervous system, including the brain and the spinal cord (GBM, 2017).

frequency rapidly increases starting in the fifth decade of life

It is estimated that GBM cases in the U.S. account for approxi‐

(Furnari et al., 2007). Therefore, the inclusion criteria for the analy‐

mately 20% of all primary CNS tumors in the adult population and

sis were patients with a confirmed diagnosis of GBM or GCG at age

almost 75% of all anaplastic gliomas (Nizamutdinov et al., 2018).

18 to 65 from the years 1985–2014. The exclusion criteria included

Glioblastoma multiforme is the most lethal primary malignant

insurance, grading, and tumor size, due to a high percentage (over

central nervous system tumor in adults (Li et al., 2015; Ohgaki &

25%) of missing data in the SEER database. The SEER database in‐

Kleihues, 2005; Stupp, Mason, & Bent, 2005). GBM incidence and

cluded patients’ insurance data from the years 2007 and onwards.

prognosis have changed over the past few years. This has been

Also, in terms of tumor size, 65% of data was missing in the data‐

explained by several risk factors, such as sex, age group, race, eth‐

base. However, glioblastoma has no clear grading system, as it is a

nicity, year of diagnosis, primary site, and surgical removal of the

type of glioma and is considered the most malignant type (type 4).

tumor (Pietschmann et al., 2015; Stummer et al., 2008). It has been

Therefore, grading was also excluded (http://www.brain
life.org/

found that the overall prognosis of patients with GBM is poor,

abstract/2017/Mesfin_F170715.pdf).

with a median survival of 14.6 months and a five‐year survival rate
of <5% (Ostrom et al., 2013; Stupp et al., 2005). A review of the
relevant literature, which included a well‐conducted systematic

2.3 | Study variables

review (Beyer et al., 2016), provided evidence of an association

The study variables included data of GBM patients (histology codes:

between survival in cases of glioblastoma and several prognos‐

ICD‐O‐3:9440/3, 9441/3) with tumors located in several locations:

tic factors, including age at diagnosis, sex, race/ethnicity, primary

supratentorial (cerebrum, frontal lobe, temporal lobe, parietal lobe,

site, and treatment (including surgery). However, no information

occipital lobe), brain overlap, and infratentorial (cerebellum, ventri‐

was available about the effect of subtypes of glioblastoma and

cle, and brainstem). In addition, primary site codes (C71.0‐C72.0)

prognosis, particularly in terms of whether survival in cases of

were extracted from the SEER database. Figure 1 shows the vari‐

giant cell glioblastoma was different from that in cases of other

ables that were analyzed.

subtypes of glioblastoma multiforme. Kozak and Moody (2009)

In addition, the SEER research data record description was used

conducted a study using the Surveillance, Epidemiology, and End

to categorize other variables such as race, which was categorized

Results (SEER) database from 1988–2004, with which they made

into White, Black, and Others. Ethnicity was also categorized into

a comparison between GCG and GBM and found that GCG had a

Non‐Spanish–Hispanic–Latino and Spanish–Hispanic–Latino. Year

better prognosis. The present study included samples from 1985

of diagnosis was categorized into years before 2010 and years 2010–

to 2014 to discover the difference in prognosis between glioblas‐

2014 due to the approval of Bevacizumab for recurrent glioblastoma

toma subtypes after the evolution of treatment modalities over

in 2010 (Johnson, Leeper, & Uhm, 2013).
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within a few years, while 84.1% of GCG patients also died from the

2.4 | Statistical analysis

tumor. The baseline characteristics of the study sample are explained

First, the population was selected from the SEER database. Then,

in Table 1, which shows that gender has a slight variation in GBM and

the characteristics of the population were described. After that, the

GCG incidences. Males are more likely to develop GBM than GCG;

general distribution of the data was examined. Next, some variables

conversely, females are more likely to develop GCG. Table 1 also

were transformed into appropriate categories (e.g., group was cat‐

shows that the incidence of GBM and GCG is not similar in relation

egorized into adults from 18 to 65 years old and elderly individuals

to age group. Hence, it is statistically significant that adults have a

59–65 years old; Li et al., 2017). The primary site was categorized

higher predisposition to developing GCG than GBM.

into supratentorial, brain overlap (including the brain ventricles and
other unspecified brain locations), and infratentorial regions.
The alpha level was set at 0.2 due to the small sample size of GCG
incidences in the SEER database.

Race also reveals some variations in terms of the two subtypes
of glioblastoma, with individuals who have a white racial back‐
ground being more prone to GBM, while individuals of other races
being more prone to GCG. The Non‐Spanish–Hispanic–Latino eth‐

A chi‐square test was used for categorical data. Categorical data were

nicity has a slightly higher incidence of GBM than GCG, while, in‐

expressed by numbers (n) and percentage (%). A univariate analysis was

versely, Spanish–Hispanic–Latinos have fewer incidences of GBM

used for variables having a p‐value < .05, while potential confounders (pa‐

than GCG. The incidence of GBM was slightly higher than the inci‐

tient's sex, age group, race, ethnicity, year of diagnosis, primary site, brain

dence of GCG before 2010; after 2010, the incidence of GCG was

overlap, and surgery) were selected and evaluated by multivariate logistic

higher. However, incidences of both tumors have decreased con‐

regression models to calculate the odds ratio with stepwise selection. A

siderably since 2010.

collinearity model was used to determine the relationship between each

The study reveals some statistically significant differences in

of the confounders for the exclusion of dependent variables. However,

terms of tumor primary site, with high statistical significance. Both

no significant relationship between the confounders was excluded.

subtypes of tumors originate more often in the supratentorial part
of the brain than elsewhere in the central nervous system. However,
GCG tumors originate more from the supratentorial site than do

2.5 | Ethical considerations

GBM tumors. It is also statistically significant that GBM risk is higher

Ethical approval was waived, since the analysis was considered non‐

in patients with no surgery or no gross total resection, while patients

human subjects research by the Florida International University

with gross total resection (GTR) have an elevated GCG risk. Table 2

Health Science Institutional Review Board.

shows that patients with GBM have a higher mortality rate than do
GCG patients. Table 3 shows that GCG has an odds ratio [OR] of
0.56 with a confidence interval of 0.53–1.44, which is independently

3 | R E S U LT S

associated with reduced mortality.
Table 2 also shows a slight difference in mortality between age

The study sample was 25,117. It included 24,909 patients with GBM

groups in relation to the two glioblastoma subtypes; this differ‐

and 208 with GCG. However, 88.3% of patients with GBM died

ence is statistically significant. It indicates that elderly patients

Independent:
Glioblastoma Mulforme (GBM) and
Giant Cell Glioblastoma (GCG)

F I G U R E 1 Variables were analyzed
using the SEER database and Stata
software

Potenal Confounders:
Sex
Age group
Race
Ethnicity
Year of diagnosis
Primary site
Surgery
Brain overlap

Dependent:
Mortality

4 of 7
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TA B L E 1 Baseline characteristics of GBM and GCG patients
from 1985–2014 in US

TA B L E 2 Mortality rate of GBM and GCG patients from
1985–2014 in US

Type of glioblastoma
Characteristics

GBM NOS
N (%)

Mortality

GCG
N (%)

p‐Value

Sex

Alive
N (%)

Dead
N (%)

2,916 (11.7)

21,993 (88.3)

33 (15.9)

175 (84.1)

Male

1,778 (12.3)

12,703 (87.7)

Female

1,162 (10.9)

9,465 (89.1)

Characteristics

p‐Value

Glioblastoma

Male

14,375 (57.7)

115 (55.3)

Female

10,534 (42.3)

93 (44.7)

Adults (18–59)

10, 221 (41.0)

120 (57.7)

Elderly (>60)

14,686 (59.0)

88 (42.3)

.481

GBM
GC

Age group

.064

Sex
<.001

Race

<.001

Age group

White

22,700 (91.3)

184 (88.5)

Black

1,169 (4.7)

12 (5.8)

Other

994 (4.0)

12 (5.8)

.318

Adults

1,464 (14.2)

8,877 (85.8)

Elderly

1,483 (10.0)

13,291 (90.0)

2,534 (11.1)

20,350 (88.9)

Race

Ethnicity

White

Non‐Spanish–
Hispanic–Latino

23,791 (95.5)

Spanish–
Hispanic–Latino

1,118 (4.5)

192 (92.3)

.027

16 (8)

Black

200 (16.9)

981 (83.1)

Others

198 (19.7)

808 (80.3)

2,741 (11.4)

21,242 (88.6)

208 (18.3)

926 (81.7)

Non‐Spanish–
Hispanic
20,719 (83.3)

171 (82.2)

2010–2014

4,190 (16.8)

37 (17.8)

Supratentorial

17,828 (71.6)

168 (80.8)

Brain overlap

6,767 (27.2)

33 (15.9)

Infratentorial

314 (1.3)

7 (3.4)

<.001

Ethnicity

Year of diagnosis
Before 2010

<.001

.71

Primary site
<.001

Spanish–
Hispanic–Latino

<.001

Abbreviations: GBM, glioblastoma multiforme; GCG, giant cell
glioblastoma.

4 | D I S CU S S I O N

Surgery
<.001

To the best of our knowledge, this study is one of the few that

None

3,287 (26.1)

13 (11.4)

No GTR

5,719 (45.5)

50 (43.9)

address the association of subtype of glioblastoma and mortality

GTR

3,574 (28.4)

51 (44.7)

in adults in the U.S. after 2010 and that involves a large sample

Abbreviations: GBM, glioblastoma multiforme; GCG, giant cell glioblas‐
toma; GTR, gross total resection; NOS, not otherwise specified.

size in GCG and GBM with the utilization of ICD‐0‐3 codes. GBM
is more common than GCG and has a higher mortality rate. On
the other hand, the current study provides statistically significant
data about ethnicity, explaining that the Spanish–Hispanic–Latino

have a worse prognosis than do adults. Glioblastoma patients

ethnicity is independently protective from both glioblastoma

with a white racial background also face a slightly increased risk

subtypes as compared to the Non‐Spanish–Hispanic ethnicity.

of death. The Spanish–Hispanic–Latino ethnicity has a lower mor‐

Furthermore, factors like being female, being age 59 to 65, and

tality rate than do Non‐Spanish–Hispanic–Latinos, as explained in

having a year of diagnosis before 2010 are independently associ‐

Table 3. The Spanish–Hispanic–Latino ethnicity is independently

ated with increased mortality.

protective from GBM and GCG (OR 0.63, CI = 0.52–0.77). GBM

This study found that elderly individuals have the highest mor‐

and GCG tumors with brain overlap have a statistically significant

tality rate among GBM and GCG patients in comparison to adults

worse outcome than do other primary tumor sites, as shown in

(p < .001). Some studies were consistent with the previous findings

Table 2.

(Hartmann et al., 2010; Lin & Wagner, 2015; Murthy, Krumholz,

Surgery also plays a role in patients’ outcomes. The mortality

& Gross, 2004; Rong et al., 2016). Therefore, age is considered

rate increases in patients with no tumor resection. As shown in

a significant predictor of survival time (Shah, Bista, & Sharma,

Table 3, the factors independently associated with increased mor‐

2016). This study also demonstrates that elderly individuals are

tality are: being female ([OR] 1.12, CI = 1.01–1.25), being age 59

more prone to having GBM than GCG, which explains the rarity of

to 65 years (OR 1.64, CI = 1.48–1.82), and being diagnosed earlier

GCG. This finding may indicate that the elderly population is more

than 2010 (OR 5.26, CI = 4.74–5.84). Table 4 shows some second‐

susceptible to GBM due to an increased chance that cells will mu‐

ary findings of the study.

tate into cancer cells. The current study demonstrated that more

|
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TA B L E 3 Odds ratio of GBM and GCG
patients from 1985–2014 in US

Adjusteda

Unadjusted
Characteristics

OR (95% CI)

5 of 7

N

OR (95% CI)

N

25,117

0.88 (0.53–1.44)

12,694

Glioblastoma
GBM

Reference

GCG

0.70 (0.5–1.02)

Abbreviations: CI, confidence interval; GBM, glioblastoma multiforme; GCG, giant cell glioblas‐
toma; OR, odds ratio.
a
Adjusted for age, sex, race, ethnicity, year of diagnosis, primary site surgery.

males are afflicted with GBM than with GCG, while more females

better survival rate than does partial resection or biopsy. Brain over‐

are afflicted with GCG (p = .481), consistent with (Colen, Wang,

lap GBM and GCG tumors are associated with higher mortality rates

Singh, Gutman, & Zinn, 2015; Matsuda et al., 2011; Nizamutdinov

than are supratentorial and infratentorial tumors (p < .001). This

et al., 2018; Ohgaki et al., 2004; Shinojima et al., 2004; Verger et

finding was similar in one study (Becker et al., 1967).

al., 2011). Another study, conducted on Black patients with GBM,

However, another study showed that the median survival time for

showed that Black males were affected by GBM more than were

both cerebellar GBM (cGBM) and supratentorial GBM (sGBM) patients is

Black females (Loukas, 2014). Therefore, GCG, an uncommon type

8 months, though sGBM had a worse prognosis as the study progressed

of glioblastoma multiforme, more often affects females. However,

(Jeswani et al., 2013). Also, patients with brain overlap tumors have a

GBM affects males more than females, regardless of race. The

higher tendency to develop GBM than GCG (p < .001). Because GBM

previous findings may be explained by genetic factors.

is more common than GCG, it affects brain overlap regions more than

The present study stated that the mortality rate is higher among

supra‐ and infratentorial regions (which are affected more by GCG,

GBM and GCG patients diagnosed before 2010 (p < .001). Also, one

p < .001). This accounts for the higher mortality rate. Non‐Spanish–

study showed that the prognosis for elderly patients with glioblas‐

Hispanic people have a higher mortality rate from GBM (88.6%, p < .001).

toma has improved since the introduction of the Stupp regimen (i.e.,

In addition, a study done on Americans with glioblastoma suggested

radiotherapy plus concomitant and adjuvant temozolomide) in 2005

that Latinos tend to have a lower incidence of GBM and present slightly

(Shah et al., 2016). This indicates that year of diagnosis has a signifi‐

younger than non‐Latino Whites (Shabihkhani et al., 2017).

cant impact on the prognosis of glioblastoma patients. However, the

However, white people were found to have the highest incidence

proportion of patients with GBM is slightly higher than the propor‐

of death from GBM and GCG as compared to individuals of other

tion of GCG patients before 2010. On the other hand, the proportion

races (p < .001).

of GCG incidences is slightly higher than the proportion of GBM inci‐
dences after 2010 (p = .71).
Patients who did not have a GTR have a higher mortality rate

4.1 | Limitations

(p < .001). Moreover, patients who had not undergone surgery or

Unfortunately, SEER registry has some unregistered variables, un‐

GTR developed GBM more often than they did GCG (p < .001).

derreported and missing data regarding surgery followed by chemo‐

Studies like (Koul, Dubey, Torri, Kakumanu, & Goyal, 2012; Pan,

or radiotherapy. There were also different styles in data coding and

Ferguson, & Lam, 2015) had similar findings, stating that GTR has a

TA B L E 4 Secondary findings of race/
ethnicity and the year of diagnosis

Unadjusted
Characteristics

OR (95% CI)

Adjusted
p‐Value

OR (95% CI)

p‐Value

Race
White

REF

Black

0.61 (0.52–0.71)

<.001

0.64 (0.52–0.79)

<.001

Others

0.50 (0.43–0.60)

<.001

0.61 (0.50–0.75)

<.001

Ethnicity
Non‐Spanish–Hispanic

REF

Spanish–Hispanic–Latino

0.57 (0.49–0.67)

<.001

0.63 (0.52–0.77)

<.001

Before 2010

5.44 (5.01–5.91)

<.001

5.26 (4.74–5.84)

<.001

2010–2014

REF

Year of diagnosis

Abbreviations: CI, confidence interval; OR, odds ratio.
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reporting, and movement of patients in and out of SEER registry
areas.
Furthermore, SEER database may have been affected by the
selection bias. In which, prospective studies might be influenced as
well. For example, immortal time bias in the assessment of surgery
followed by chemo‐ or radiotherapy effectiveness.

5 | CO N C LU S I O N S
GCG was not statistically significant in terms of its association with
reduced mortality. Factors such as being female, being age 59 to 65,
and having a year of diagnosis before 2010 were independently as‐
sociated with increased mortality. The Spanish–Hispanic ethnicity
was independently protective from GBM and GCG as compared to
the Non‐Spanish–Hispanic ethnicity. Additional studies should be
conducted on GBM and GCG patients with the inclusion of important
factors such as tumor size/activity, disease stage, treatment history,
and insurance.
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